GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
== Products and markets == Vacuum technology has always been an important utility in the production of electronics. The first TV and radio technologies emerged in the 1920s and 1930s, and Edwards Vacuum delivered vacuum pumps for the production of valve amplifiers, which enabled transmission and reception. In its initial years, Edwards Vacuum imported vacuum equipment from Germany's Leybold. A freeze-drying method using vacuum chambers was patented in the 1930s. During World War II, the technology was further perfected and expanded to freeze-dry instant coffee, but also blood plasma and penicillin. Penicillin itself was also produced using vacuum technology. World War II marked an acceleration in technological development for vacuum technology. Vacuum pump manufacturers innovated their products and new applications for vacuum emerged. This included but wasn't limited to, the development of radar transmitters and receivers used in operations, glass coating of binoculars and windscreens, infrared systems, used for night flying and operations, foil coating, which confused radar systems and the introduction of freeze-drying to remove moisture, applied to various pharmaceutical processes.
In October 2023, Newsom vetoed several bills aimed at expanding access to housing assistance including the California Social Housing Act. One was a bill to repurpose unused state-owned land for affordable housing, which he said infringed on state sovereignty. Another would have expanded the number of people who qualify for state housing assistance. A third would have mandated that Medi-Cal cover the cost of housing assistance. Newsom has signed the Abundant and Affordable Homes Near Transit Act, Affordable Housing on Faith and Higher Education Lands Act, California Assembly Bill 2097 (2022) and California HOME Act. In August 2024, Newsom warned counties that did not remove their homeless encampments that failure to do so would result in their state funding being cut off the next year. He issued this warning after personally visiting and clearing out a Los Angeles homeless encampment without notifying the city beforehand. In September 2024, Newsom vetoed Assembly Bill 1840, which sought to prohibit the disqualification of applicants to California Housing Finance Agency home purchase assistance programs based solely on their immigration status.
Nutritional yeast in particular is naturally low in fat and sodium and a source of protein and vitamins as well as other minerals and cofactors required for growth. Many brands of nutritional yeast and yeast extract spreads, though not all, are fortified with vitamin B12, which is produced separately by bacteria. In 1920, the Fleischmann Yeast Company began to promote yeast cakes in a "Yeast for Health" campaign. They initially emphasized yeast as a source of vitamins, good for skin and digestion. Their later advertising claimed a much broader range of health benefits, and was censured as misleading by the Federal Trade Commission. The fad for yeast cakes lasted until the late 1930s. Yeast cell walls are used as a source of dietary fiber. Specifically, the glucan part is marketed as "yeast β-glucan" and the mannan part is further processed into mannan-oligosaccharide (MOS).
Sources: en.wikipedia.org
==== Miscellaneous afrotherian research ==== Alcalá et al. (2026) describe new fossil material of Pliohyrax graecus from the Miocene (Vallesian) strata from the La Roma 2 site (Province of Teruel, Spain), representing the most complete hyracoid record from the Iberian Peninsula reported to date. Raynaud et al. (2026) interpret the composition of the Eocene plant assemblage from the Bultu-Zile site (Meryemdere Formation; Turkey), reconstructed on the basis of study of the palynoflora from this site, as indicating that embrithopods from the site lived in a swamp-freshwater environment, representing one of the first embrithopod records outside mangrove-dominated ecosystems. Evidence from the study isotopic composition of tooth enamel of Eocene embrithopods from Balkanatolia, interpreted as indicative of the studied mammals living in fully terrestrial rather than semi-aquatic environment, is presented by Robert et al. (2026).
The Yumburger (also spelled as Yum Burger, or Yum!), one of the first products sold by Jollibee, is a hamburger containing a beef patty topped with mayonnaise. In The Daily Telegraph, Michael Deacon described the Yumburger as "a slim, floppy, somewhat damp hamburger slathered with a strangely sweet mayo" in his three-star review of a Jollibee location in London. In 2017, Jollibee introduced the Aloha Yumburger. That same year, an advertising video on YouTube about the Yumburger went viral in the Philippines. A 2019 Yumburger commercial about love on Father's Day was the subject of memes. Merchandise depicting the Yumburger was released in 2018 as a collectible toy set with the Jolly Kiddie Meal.
== Medical uses == The primary target for the development of FIAU was the treatment of chronic hepatitis B virus (HBV) infection. FIAU is a nucleoside analogue, meaning that the molecule is similar to the building blocks of deoxyribonucleic acid, DNA. Once it enters the body and it is phosphorylated by viral thymidine kinase the FIAU is activated. The FIAU will then be incorporated into the viral DNA while the virus is dividing. The virus will begin building a new DNA strand and use FIAU as a ‘building block’, but as it is an analogue and not a real nucleotide the DNA chain cannot be completed. FIAU was a potent inhibitor of HBV replication, thus resulting in a large decrease in serum HBV DNA levels. FIAU (and its parent drug FIAC) was also studied for the use in treating herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). Nowadays FIAU is an important compound in the field of drug-induced liver injury research. FIAU, despite its early promise, was never put on the market and has never been available for medicinal use. In the initial clinical trials FIAU was a potent inhibitor of the HBV replication, as patients experienced a large decrease in serum HBV DNA levels. And in the high-dosed groups the HBV DNA was reduced by 70 to 95%. But even though the treatment was very promising, the antiviral effect was almost always temporary.
Beryllium (4Be) has 11 known isotopes and 3 known isomers, but only one of these isotopes (9Be) is stable and a primordial nuclide. As such, beryllium is considered a monoisotopic element. It is also a mononuclidic element, because its other isotopes have such short half-lives that none are primordial and their abundance is very low. Beryllium is unique as being the only monoisotopic element with an even number of protons (even atomic number) and also has an odd number of neutrons; the 25 other monoisotopic elements all have odd numbers of protons (odd atomic number), and even of neutrons, so the total mass number is still odd. Of the 10 radioisotopes of beryllium, the most stable are 10Be with a half-life of 1.387 million years and 7Be with a half-life of 53.22 days. All other radioisotopes have half-lives shorter than 15 seconds. The 1:1 neutron–proton ratio seen in stable isotopes of many light elements (up to oxygen, and in elements with even atomic number up to calcium) is prevented in beryllium by the extreme instability of 8Be toward splitting into two 4He nuclei, which may be seen either alpha decay or a type of fission; in any case the half-life is only 8.2×10−17 s, short enough to normally be considered unbound. This, as with the relative instability of all lithium, beryllium, and boron isotopes, is favored due to the extremely tight binding of the helium-4 nucleus. Beryllium is prevented from having a stable isotope with 4 protons and 6 neutrons by the very lopsided neutron–proton ratio for such a light element.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.